Most Recent Articles by Lauren Grygotis, Editor
TNFi treatment is not associated with increased risk for cancer recurrence in patients with rheumatoid arthritis
Data indicate that drug-naive new onset systemic lupus erythematosus was likely to involve silent cardiac impairment.
The FDA has released a Biosimilar Action Plan to promote competition and affordability across the market for biologic and biosimilar products.
Results from a phase 3 study show positive results for ixekizumab in patients with ankylosing spondylitis.
A pooled analysis compared the efficacy and safety of anti-TNF biosimilars with their reference products.
More Articles by Lauren Grygotis, Editor
Certolizumab Pegol Demonstrates Positive Results in Phase 3 Trial for Nonradiographic Axial SpondyloarthritisMay 17,2018
Rheumatology Advisor Articles
- Promising Antibody Markers Identified for aPL-Related Pregnancy Complications
- Comorbid Fibromyalgia Influences Disease Activity, Quality of Life in Axial Spondyloarthritis
- Efficacy of ABT-122 Maintained in Psoriatic Arthritis, Rheumatoid Arthritis at 36 Weeks
- Knee Load Associated With Increased Walking Pain in Osteoarthritis
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Genetic Screening May Predict Osteoporosis, Fracture Risk
- Exploring the Clinical Implications of Cannabinoid Use in Rheumatoid Arthritis
- Diagnosing Lyme Disease in Children With Neuropsychiatric Illness
- Predicting Primary Nonresponse to Methotrexate in Rheumatoid Arthritis
- Prednisone, Prednisolone Does Not Adversely Affect Bone Mineral Density in RA
- Characteristics of Early-Onset SLE Distinguished From Mimicking Conditions
- Uric Acid Predicts AKI Risk After Cardiac Surgery
- Examining Gaps in Mental Health Care Among Youth With Juvenile Rheumatic Disease
- AMA Proposes Policy Opposing Medicaid 'Lockout' Provisions
- TNFi Not Linked to Increased Risk for Cancer Recurrence in Rheumatoid Arthritis